We'll never know if this would be useful post stroke since there is NO STROKE LEADER to go to to update the stroke strategy and start research on these questions. You're screwed as long as we don't have stroke survivors running stroke associations.
Allopregnanolone as a Therapeutic to Regenerate the Degenerated Brain
Chapter
First Online:
Part of the ISGE Series book series (ISGE)
Abstract
Neurosteroids
regulate both regeneration and repair systems in the brain. Among this
class of molecules, allopregnanolone (Allo) is the first regenerative
therapeutic that has been extensively investigated in animal models and
more recently in humans for its capacity to promote regeneration in the
central and peripheral nervous system. In preclinical analyses, Allo
induced generation and survival of new neurons in the hippocampus of
aged mice and in transgenic mouse models of Alzheimer’s disease (AD),
which was associated with restoration of learning and memory function.
Allo is a proliferative factor for both neural stem cells and
pre-progenitor oligodendrocytes, increasing both the number of newly
generated cells and their survival. Safety characteristics of Allo
regulation of neurogenesis indicate that the regenerative system it
affects is tightly regulated with closely guarded thresholds for both
activation and magnitude of proliferation. In the brain of mice with AD,
Allo increased liver X receptor and pregnane X receptor expression,
reduced ß-amyloid and microglial activation, and increased markers of
white matter generation. Results of preclinical studies indicate that an
optimal treatment regimen of Allo to promote endogenous regeneration is
one that is administered once per week over the course of several
months. Allo dose and frequency of exposure are determining factors
regulating its therapeutic efficacy. Previous and current human safety
exposure data supported by extensive preclinical efficacy data are
strong foundations for the clinical development of Allo as a therapeutic
to regenerate the degenerated brain.
No comments:
Post a Comment